- Home
- PLX vs INFU Comparison
PLX vs INFU Comparison
Compare PLX & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- INFU
- Stock Information
- Founded
- PLX 1993
- INFU 2005
- Country
- PLX United States
- INFU United States
- Employees
- PLX N/A
- INFU N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- INFU Medical/Dental Instruments
- Sector
- PLX Health Care
- INFU Health Care
- Exchange
- PLX Nasdaq
- INFU Nasdaq
- Market Cap
- PLX 127.4M
- INFU 124.0M
- IPO Year
- PLX 1998
- INFU N/A
- Fundamental
- Price
- PLX $1.54
- INFU $8.83
- Analyst Decision
- PLX Strong Buy
- INFU Strong Buy
- Analyst Count
- PLX 1
- INFU 1
- Target Price
- PLX $15.00
- INFU $12.00
- AVG Volume (30 Days)
- PLX 498.6K
- INFU 162.9K
- Earning Date
- PLX 08-14-2025
- INFU 08-05-2025
- Dividend Yield
- PLX N/A
- INFU N/A
- EPS Growth
- PLX N/A
- INFU 2168.02
- EPS
- PLX 0.05
- INFU 0.24
- Revenue
- PLX $59,764,000.00
- INFU $139,886,000.00
- Revenue This Year
- PLX $10.00
- INFU $11.06
- Revenue Next Year
- PLX $83.13
- INFU $7.86
- P/E Ratio
- PLX $32.18
- INFU $37.21
- Revenue Growth
- PLX 0.18
- INFU 8.13
- 52 Week Low
- PLX $0.82
- INFU $4.61
- 52 Week High
- PLX $3.10
- INFU $9.97
- Technical
- Relative Strength Index (RSI)
- PLX 53.22
- INFU 84.57
- Support Level
- PLX $1.41
- INFU $5.43
- Resistance Level
- PLX $1.52
- INFU $6.31
- Average True Range (ATR)
- PLX 0.06
- INFU 0.38
- MACD
- PLX 0.01
- INFU 0.29
- Stochastic Oscillator
- PLX 56.52
- INFU 98.27
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.